Lygature Revenue and Competitors
Estimated Revenue & Valuation
- Lygature's estimated annual revenue is currently $12.7M per year.
- Lygature's estimated revenue per employee is $238,925
Employee Data
- Lygature has 53 Employees.
- Lygature grew their employee count by 6% last year.
Lygature Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 53 | 6% | N/A | N/A |
#2 | $54.9M | 226 | -3% | N/A | N/A |
#3 | $33.4M | 156 | 22% | N/A | N/A |
#4 | $34.6M | 133 | -4% | N/A | N/A |
#5 | $257.3M | 1025 | -6% | N/A | N/A |
#6 | $3.2M | 16 | 45% | N/A | N/A |
#7 | $257.3M | 1025 | -6% | N/A | N/A |
#8 | $16.7M | 83 | -31% | N/A | N/A |
#9 | $81.2M | 404 | 106% | N/A | N/A |
What Is Lygature?
Lygature drives the development of new medical solutions for patients by managing public-private partnerships that bring together industry, academia and society. Every day we pioneer solutions in the areas of medical technology and pharmacotherapy to serve patients worldwide. Lygature is a not-for-profit organization based in the Netherlands. We build upon the legacy of the Center for Translational Molecular Medicine (CTMM) and Top Institute Pharma (TI Pharma).
keywords:N/A
N/A
Total Funding
53
Number of Employees
$12.7M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lygature News
... the global umbrella of the AMR Accelerator, the Gram-Negative Antibacterials NOW (GNA NOW) consortium, led by Evotec SE and Lygature, ...
In a project with the Dutch drug-discovery nonprofit Top Institute Pharma, now a subsidiary of the nonprofit Lygature, MercachemSyncom ...
The new GNA NOW project, led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI), will work on the ...
Other Companies in Utrecht
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $11.1M | 53 | 18% | $42M |
#2 | N/A | 53 | 23% | N/A |
#3 | N/A | 54 | 46% | N/A |
#4 | $7.5M | 54 | 35% | N/A |
#5 | $7.5M | 54 | 17% | N/A |